Head to Head Contrast: Hill-Rom Holdings (HRC) & Meridian Bioscience (VIVO)

Hill-Rom Holdings (NYSE: HRC) and Meridian Bioscience (NASDAQ:VIVO) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitabiliy, institutional ownership, dividends, earnings and analyst recommendations.

Dividends

Hill-Rom Holdings pays an annual dividend of $0.72 per share and has a dividend yield of 0.9%. Meridian Bioscience pays an annual dividend of $0.50 per share and has a dividend yield of 3.3%. Hill-Rom Holdings pays out 31.0% of its earnings in the form of a dividend. Meridian Bioscience pays out 70.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Meridian Bioscience has raised its dividend for 6 consecutive years. Meridian Bioscience is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Profitability

This table compares Hill-Rom Holdings and Meridian Bioscience’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Hill-Rom Holdings 5.80% 19.77% 5.64%
Meridian Bioscience 15.02% 18.02% 12.00%

Valuation and Earnings

This table compares Hill-Rom Holdings and Meridian Bioscience’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Hill-Rom Holdings $2.68 billion 2.01 $458.00 million $2.32 35.26
Meridian Bioscience $198.60 million 3.24 $55.72 million $0.71 21.48

Hill-Rom Holdings has higher revenue and earnings than Meridian Bioscience. Meridian Bioscience is trading at a lower price-to-earnings ratio than Hill-Rom Holdings, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

83.9% of Hill-Rom Holdings shares are owned by institutional investors. Comparatively, 86.4% of Meridian Bioscience shares are owned by institutional investors. 2.2% of Hill-Rom Holdings shares are owned by insiders. Comparatively, 2.3% of Meridian Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Hill-Rom Holdings has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Meridian Bioscience has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Hill-Rom Holdings and Meridian Bioscience, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hill-Rom Holdings 0 1 4 0 2.80
Meridian Bioscience 1 4 0 0 1.80

Hill-Rom Holdings currently has a consensus target price of $88.20, indicating a potential upside of 7.81%. Meridian Bioscience has a consensus target price of $14.33, indicating a potential downside of 6.01%. Given Hill-Rom Holdings’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Hill-Rom Holdings is more favorable than Meridian Bioscience.

Summary

Hill-Rom Holdings beats Meridian Bioscience on 10 of the 17 factors compared between the two stocks.

Hill-Rom Holdings Company Profile

Hill-Rom Holdings, Inc. is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions. The Company sells and rents its specialty frames and surfaces, and mobility solutions, as well as its clinical workflow solutions, in the United States and Canada through its North America Patient Support Systems segment, and in regions outside of the United States and Canada through its International Patient Support Systems segment. Its Front Line Care segment globally sells and rents respiratory care products, and sells medical diagnostic equipment and a diversified portfolio of devices that assess, diagnose, treat and manage a range of illnesses and diseases. Under its Surgical Solutions segment, the Company sells its surgical products globally.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Its segments include Diagnostics and Life Science. The Diagnostics segment includes manufacturing operations in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia.

Receive News & Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related companies with our FREE daily email newsletter.

 


Latest News

Todd Frazier Traded to Yankees for Blake Rutherford and Others
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Todd Frazier Trade to Boston Appears to Be Decided
Todd Frazier Trade to Boston Appears to Be Decided
Chicago White Sox Continue Rebuild Without Jose Quintana
Chicago White Sox Continue Rebuild Without Jose Quintana
Mike Trout Returns from Injury With Single and Stole Base
Mike Trout Returns from Injury With Single and Stole Base
Chicago Cubs Strengthen Rotation Through Trade for Jose Quintana
Chicago Cubs Strengthen Rotation Through Trade for Jose Quintana


Leave a Reply

 
© 2006-2017 BBNS.